早期胃癌治愈性内镜黏膜下剥离术后异时性复发的新的风险分层
这项回顾性队列研究纳入1115例因分化型早期胃癌按扩大标准行治愈性内镜黏膜下剥离术的患者,随访中位50.1个月,按同步肿瘤、男性伴胃体肠化生等分为3组,5年和7年异时性复发累积风险分别为15.1%和26.1%、5.6%和9.3%、3.8%和4.9%(P < .001)。
要点
- 伴同步肿瘤者5年和7年异时性复发累积风险分别为15.1%和26.1%。
- 男性伴胃体肠化生者5年和7年累积风险分别为5.6%和9.3%。
- 男性无胃体肠化生或女性5年和7年累积风险分别为3.8%和4.9%。
核心结论
- 推荐对伴同步肿瘤的患者进行超过5年的每年细致内镜监测以发现异时性胃癌。
- 作者认为男性伴胃体肠化生患者的内镜监测也可延长至5年以上。
研究设计与样本
- 回顾性队列研究,纳入2005年至2014年单家三级医院1115例因分化型早期胃癌按扩大标准行治愈性内镜黏膜下剥离术的患者,每年内镜随访中位50.1个月,评估幽门螺杆菌和组织学肠化生,采用Kaplan-Meier法和Cox回归进行风险分层。
主要发现
- 共识别3个风险组:第1组为伴同步肿瘤的患者,第2组为男性伴胃体肠化生,第3组为男性无胃体肠化生或女性。
- 第1组5年和7年异时性复发累积风险分别为15.1%(95% CI,7.7-22.5)和26.1%(95% CI,14.9-37.3)。
- 第2组5年和7年累积风险分别为5.6%(95% CI,3.1-8.1)和9.3%(95% CI,5.4-13.2)。
- 第3组5年和7年累积风险分别为3.8%(95% CI,1.6-6.0)和4.9%(95% CI,2.4-7.4),三组比较P < .001(log-rank检验)。
- 第1组和第2组异时性胃癌发生率在5年后仍持续增加,第3组则未增加;数据不足以显示幽门螺杆菌根除与异时性复发之间存在关联。
关键数值与推荐
- 伴同步肿瘤的患者:推荐每年细致内镜监测超过5年。
- 男性伴胃体肠化生:内镜监测也可延长至5年以上。
临床怎么用
- 对伴同步肿瘤的早期胃癌治愈性内镜黏膜下剥离术后患者,推荐每年细致内镜监测并超过5年。
- 对男性伴胃体肠化生的患者,作者认为内镜监测也可延长至5年以上。
局限性
- 数据不足以显示幽门螺杆菌根除与异时性复发之间存在关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: This study stratified the risk of developing metachronous gastric cancer (MGC) after curative endoscopic submucosal dissection (ESD) of early gastric cancer (EGC) to enable customization of endoscopic surveillance for MGC. METHODS: A total of 1115 patients who underwent curative ESD based on the expanded criteria for differentiated EGC from 2005 to 2014 at a single tertiary hospital were enrolled in this retrospective cohort study. They were followed up with annual endoscopy for a median of 50.1 months. Helicobacter pylori and histologic intestinal metaplasia (IM) were evaluated. The Kaplan-Meier method and Cox regression analysis were used for risk stratification. RESULTS: Three risk groups were identified: group 1 comprised patients with a synchronous neoplasm; group 2 comprised male patients with corpus IM; and group 3 comprised male patients without corpus IM or female patients. The 5- and 7-year cumulative risks (95% confidence interval [CI]) for metachronous recurrence were 15.1% (95% CI, 7.7-22.5) and 26.1% (95% CI, 14.9-37.3), respectively, in group 1; 5.6% (95% CI, 3.1-8.1) and 9.3% (95% CI, 5.4-13.2), respectively, in group 2; and 3.8% (95% CI, 1.6-6.0) and 4.9% (95% CI, 2.4-7.4), respectively, in group 3 (P < .001 by log-rank test). The incidence of MGCs increased constantly even after 5 years in groups 1 and 2 but not in group 3. There was not enough evidence to show an association between H pylori eradication and metachronous recurrence in the data. CONCLUSIONS: Meticulous annual endoscopic surveillance for MGC for more than 5 years is recommended for patients with synchronous neoplasm. Endoscopic surveillance may also be extended beyond 5 years in male patients with corpus IM.
引用
- Yang HJ, Kim SG, Lim JH, et al. Novel risk stratification for metachronous recurrence after curative endoscopic submucosal dissection for early gastric cancer. Gastrointest Endosc. 2017. PMID: 28713064. doi:10.1016/j.gie.2017.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。